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Abstract
Background: Platelets have been involved in both immune surveillance and host
defense against severe infection. To date, whether platelet phenotype or other
hemostasis components could be associated with predisposition to sepsis in critical
illness remains unknown. The aim of this work was to identify platelet markers that
could predict sepsis occurrence in critically ill injured patients.
Methods: This single-center, prospective, observational, 7-month study was based
on a cohort of 99 non-infected adult patients admitted to ICUs for elective cardiac
surgery, trauma, acute brain injury, and post-operative prolonged ventilation and
followed up during ICU stay. Clinical characteristics and severity score (SOFA) were
recorded on admission. Platelet activation markers, including fibrinogen binding to
platelets, platelet membrane P-selectin expression, plasma soluble CD40L, and
platelet-leukocytes aggregates were assayed by flow cytometry at admission and
48 h later, and then at the time of sepsis diagnosis (Sepsis-3 criteria) and 7 days later
for sepsis patients. Hospitalization data and outcomes were also recorded.
Methods: Of the 99 patients, 19 developed sepsis after a median time of 5 days.
These patients had a higher SOFA score at admission; levels of fibrinogen binding to
platelets (platelet-Fg) and of D-dimers were also significantly increased compared to
the other patients. Levels 48 h after ICU admission no longer differed between the
two patient groups. Platelet-Fg % was an independent predictor of sepsis (P = 0.
0031). By ROC curve analysis, cutoff point for Platelet-Fg (AUC = 0.75) was 50%. In
patients with a SOFA cutoff of 8, the risk of sepsis reached 87% when Platelet-Fg
levels were above 50%. Patients with sepsis had longer ICU and hospital stays and
higher death rate.
Conclusions: Platelet-bound fibrinogen levels assayed by flow cytometry within 24 h
of ICU admission help identifying critically ill patients at risk of developing sepsis.
Keywords: Sepsis, Prediction, Flow cytometry, Platelet markers, Fibrinogen, SOFA,
Biomarker
Background
Despite sustained research on the immune pathophysiology of sepsis, sepsis occurrence
remains the leading cause of mortality (20–50%) in the intensive care unit (ICU) [1, 2].
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Therefore, the identification of predictive biomarkers of sepsis is instrumental to im-
prove ICU patients’ outcome. The Third International Consensus Task Force (Sepsis-3)
defines sepsis as a “life-threatening organ dysfunction caused by a dysregulated host re-
sponse to infection”. In this concept, growing experimental and preclinical evidence in-
dicates that platelets could play an active role either in immune surveillance or in the
response to infection. Indeed, in addition to their role in hemostasis and thrombosis,
several studies in animal models suggest a contribution of platelets to infectious dis-
eases due to their ability to influence innate and adaptive immune responses [3]. First,
platelets may act as sentinels of the immune system. They indeed express many major
receptors of the innate immune system, including most Toll-like receptors. Platelets
are able to recognize molecular features of microbes and secrete many immunomodu-
latory mediators essential for alerting and recruiting cells of the immune system [4–7].
Second, platelets may contain infection both directly and through functional interac-
tions with immune cells [8]. Platelets produce various antimicrobial molecules, includ-
ing defensins [9], thrombocidins [10], and kinocidins, and they are able to interact with
and kill bacteria directly [11]. For instance, it has been shown that activated platelets fa-
cilitate the clearance of adherent Streptococci in experimental infective endocarditis
[12]; β-defensins released from platelets activated by the Staphylococcus aureus α-toxin
impair bacterial growth and induce neutrophil extracellular trap formation [13]. Plate-
lets also help trap blood pathogens on Kupffer cells in hepatic sinusoids, which limits
systemic infection [14]. Notably, platelets express CD40L, an essential player in host
defense against infection that mediates interactions between platelets, antigen-
presenting cells, and lymphocytes [15].
In overwhelming sepsis, platelets contribute to activation of the procoagulant cas-
cade and ensuing complications linked to microvascular thrombosis and subsequent
organ dysfunction [16]. It has been demonstrated that critically ill injured adult pa-
tients, such as burn, trauma, or cardiac surgery patients, experience susceptibility
to sepsis because of innate and adaptive immune reprogramming due to the insult
[17, 18]. However, whether platelets may participate in dysregulated host response
to infection leading to sepsis remains unclear. One recent study showed that im-
mature platelet fractions (IPF) could predict sepsis occurrence in critically ill sub-
jects [19]. Further, in severe trauma, platelet activation and leukocyte-platelet
aggregate formation have been incriminated in the pathogenesis of tissue lesions
leading to organ failure [20]. The present prospective observational study hypothe-
sized that platelet activation markers triggered by common injuries may help pre-
dicting occurrence of sepsis in specific ICU patient populations.
Methods
Study patients
This was a single-center, prospective, observational, 7-month study based on a cohort
of 99 consecutive adult patients, expected to stay for at least 48 h in tertiary ICU.
Inclusion criteria included elective cardiac surgery (coronary artery bypass grafting or
valve replacement), trauma, invasive ventilation >48 h for reasons other than sepsis,
and acute brain injury (including subarachnoid, subdural, intra-parenchymal
hemorrhage, and ischemic stroke). Patients were excluded from the study if they
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received oral or parenteral antibiotics other than for prophylaxis and if they were
treated with any immunosuppressive agent except substitutive doses of corticosteroids,
suffered from chronic hepatitis B or C, HIV, solid organ, or hematologic proliferative
disease.
Characteristics at ICU admission
Upon admission to ICU, the following baseline characteristics were recorded: gender,
age, type of admission (surgical or medical), history of diabetes and cardiovascular
disease, previous treatment by vasopressor, prophylactic antibiotics, aspirin, and antico-
agulants (anti-αIIbβ3). The sequential organ failure assessment (SOFA) score was
computed. Blood samples were collected within 24 h (T1) for flow cytometry analyses
(see the “Flow cytometry” section below). The following laboratory parameters were
also assayed: C-reactive protein (CRP, mg/ml), fibrinogen (g/l), partial thromboplastin
time (PTT, s), prothrombin time index (%), platelet count (k/μl), D-dimers (μg/l), and
WBC count (K/μl). The ISTH scoring system for overt disseminated intravascular
coagulation (DIC) was calculated based on Toh et al. [21].
Follow-up and sepsis occurrence
Patients were sampled again 48 h (T2) after admission, on the day of diagnosis of sepsis
(Tx), and 7 days later. All blood specimens were analyzed by flow cytometry as in T1.
A time line diagram is provided as Additional file 1: Figure S1. Criteria for severe sepsis
or septic shock are in agreement with the new definitions of sepsis (Sepsis-3) [22]. For
each study patient, the following data were also collected: length of ICU and of hospital
stay (days), duration of ventilation (days) if required, administration of vasopressor dur-
ing ICU admission, antibiotic treatment, use of curative antibiotics, red blood cell
transfusion, plasma transfusion and platelet transfusion, and hemofiltration or intermit-
tent hemodialysis during or after ICU stay. In case of death, time was also recorded. In
case of discharge from the hospital, follow-up was at least 1 year.
Flow cytometry
Citrated whole blood was collected through an indwelling arterial catheter. Samples were
processed within maximum 1 h following blood drawing. Platelet activation levels were
assessed by measuring the expression of P-selectin (PS), a marker of degranulation, and fi-
brinogen (Fg) binding, as a result of integrin αIIbβ3 activation, on cell surface. Specifically,
blood samples were fixed and incubated with peridinin-chlorophyll protein-linked
(PerCP)-anti-CD61 antibodies (BD Biosciences), fluorescein isothiocyanate-linked (FITC)-
anti-fibrinogen antibodies (Dako), and phycoerythrin-linked (PE)-anti-CD62P antibodies
(BD Biosciences). Levels of platelet activation markers were determined by recording me-
dians of FITC and PE fluorescence intensity (MFI) in platelets (CD61 positive cells) and
percentages (%) of fibrinogen-positive (FITC) or CD62P-positive (PE) platelets on a FACS
Verse flow cytometer (BD Biosciences). Data were analyzed using the BD FACSuite soft-
ware. Platelets-monocytes and platelets-neutrophils aggregates were analyzed in citrated
whole blood samples using an antibody panel, including anti-CD45-V500, anti-CD14-
APC (monocytes), anti-CD15-PE (neutrophils), and anti-CD61-PerCP. Medians of CD61-
PerCP fluorescence intensity in CD14-positive and CD15-positive cells, and percentages
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of cells double positive for CD61 and CD14, or CD61 and CD15 were recorded as above.
In all cases, threshold of positivity was set by use of marker-specific antibodies or their
corresponding IgG isotype controls in blood samples that were left unstimulated or acti-
vated with a supra-optimal dose of collagen-related peptide. Plasma was prepared from
the citrated whole blood samples to quantify plasma levels of TNFα, IL10, sCD40L,
IL17A, IL6, IL7, and IFNγ, all expressed in pg/ml. Cytokine levels were measured using
customized multiplex BD™ Cytometric Bead Array on the FACSVerse System. Analysis
was performed with the FCAP Array™ software.
Statistics
Results were expressed as mean and standard deviation for quantitative data and as
median and interquartile range (IQR) for durations. For categorical findings, frequency
tables were used. The predictive value of sepsis was assessed for each baseline variable
by logistic regression analysis. Then variables significant at P < 0.10 were combined in a
stepwise logistic regression analysis to identify independent baseline predictors of
sepsis. The odds ratio (OR) with 95% confidence interval (95%CI) and ROC curve ana-
lysis with area under the curve (AUC) were used to quantify the ability of the selected
predictors to discern patients who will later develop sepsis. The Youden method was
applied to define an optimal cutoff point for platelet marker predictors and SOFA
score. Comparisons of hospital data and outcomes between septic and non-septic pa-
tients were done by the Kruskal-Wallis test for continuous variables and the Fisher
exact test for categorical variables. Data recorded on the same patients but at different
time points were compared by the Wilcoxon signed rank test. Results were considered
significant at the 5% critical level (P < 0.05). All statistical calculations were performed
with SAS (version 9.4) and R (version 3.0.3).
Results
Baseline characteristics of patients
The baseline ICU admission characteristics of the 99 study patients are displayed in
Additional file 2: Table S1. There were 60 men and 39 women aged 64 ± 15 years. The
type of admission was surgical for 86 patients, and the main reason was predomin-
antly cardiac surgery (68.7%). Seventeen patients had a history of diabetes and 79 of
cardiovascular disease. Ten patients received vasopressor before admission, 67 re-
ceived prophylactic antibiotics during surgery, 53 were under aspirin, 3 were under
αIIbβ3 antagonist, and 14 patients were taking anticoagulant (only prophylactic doses
of low molecular weight heparin). The mean SOFA score was 6.0 ± 3.3. Data of
routine biological parameters and flow cytometry results upon admission and 48 h
later are displayed in Additional file 1: Table S2. No difference was evidenced between
aspirin (n = 53) or anticoagulant users (n = 14) and non-users in terms of their
biological profile (data not shown).
Sepsis occurrence
Of the 99 study subjects, 19 (19.2%) developed sepsis after a median time of 5 [IQR 3–7]
days and 80 did not. As seen in Table 1, age, gender, type of admission, history of diabetes,
use of vasopressor, anti-platelet, or anticoagulation medication use were not associated
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with sepsis development. By contrast, patients who later developed sepsis presented with
higher SOFA score at admission. They were also predominantly admitted for acute brain
surgery or prolonged ventilation and lacked prophylactic antibiotics prior to admission.
Complementary results of septic compared to non-septic patients are shown in Additional
file 2: Table S3.
When considering laboratory tests and flow cytometry parameters recorded within
24 h of admission to ICU (Table 2), D-dimers and fibrinogen binding to platelets (plate-
let-Fg expressed as MFI or %) were markedly higher (P < 0.001) in patients who later
Table 1 Predictive value of patient demographic and baseline clinical data for sepsis development
during ICU stay
Variable Development of sepsisa P valueb
No (N = 80) Yes (N = 19)
Age (years) 65 ± 15 62 ± 15 0.46
Gender 0.80
Male 48 (80) 12 (20)
Female 32 (82.1) 7 (17.9)
Category of admission 0.70
Surgical 70 (81.4) 16 (18.6)
Medical 10 (76.9) 3 (23.1)
Reason for admission 0.0052
Cardiac surgery 61 (89.7) 7 (10.3)
Acute brain injury 6 (50) 6 (50)
Trauma 10 (76.9) 3 (23.1)
Ventilation >48 h 3 (50) 3 (50)
Score at admission
SOFA 5.2 ± 2.7 9.6 ± 3.1 <0.0001
Diabetes 0.62
Yes 13 (76.5) 4 (23.5)
No 67 (81.7) 15 (18.3)
Cardiovascular disease 0.012
Yes 68 (86.1) 11 (13.9)
No 12 (60) 8 (40)
Vasopressor before the admission 0.091
Yes 6 (60) 4 (40)
No 74 (83.2) 15 (16.8)
Prophylactic antibiotics 0.0005
Yes 61 (91) 6 (9)
No 19 (59.4) 13 (40.6)
Aspirin 0.93
Yes 43 (81.1) 10 (18.9)
No 37 (80.4) 9 (19.6)
Anticoagulant 0.24
Yes 13 (92.9) 1 (7.1)
No 67 (78.8) 18 (21.1)
aMeans ± SD for quantitative variable and numbers (%) for qualitative parameters
bLogistic regression
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developed sepsis. To a lesser extent, ISTH DIC score (P < 0.05) also differed between
septic and non-septic patients. Interestingly, levels of sCD40L, P-selectin on circulating
platelets (MFI or %), platelets-monocytes, and platelets-neutrophils aggregates were not
associated with sepsis occurrence. Platelet-Fg correlated weakly with platelet P-selectin
(r = 0.32378, P = 0.0011, N = 98), and plasma levels of D-dimers (r = 0.35502, P = 0.0004,
N = 96) and fibrinogen (r = 0.34592, P = 0.0005, N = 98). No significant correlation was
found with platelet count (r = 0.071, P = 0.49, N = 98), sCD40L (r = −0.10377, P = 0.3222,
N = 93), or cytokine levels. Flow cytometry parameters recorded 48 h after admission were
not associated with sepsis occurrence, although a tendency (P < 0.10) remained for
platelet-Fg (data not shown). When looking at serial platelet-Fg levels in patients
who developed sepsis, a significant increase was observed and a peak was reached
on the day of sepsis (Fig. 1). By contrast, sCD40L remained fairly stable as sepsis
developed (Additional file 1: Figure S2). D-dimers and platelet P-selectin levels
Table 2 Predictive value of laboratory tests assessed at admission for sepsis development during
ICU stay
Variable Development of sepsisa P valueb
No (N = 80) Yes (N = 19)
Routine
CRP (mg/L) 14.1 ± 37.7 29.1 ± 61.7 0.053
Fibrinogen (g/L) 2.6 ± 0.99 3.3 ± 2.0 0.11
PTT (s) 14.4 ± 1.7 14.4 ± 3.3 0.78
Prothrombin Time Index (%) 66.3 ± 15.6 69.7 ± 19.4 0.61
Platelet count (103/μL) 124 ± 55 133 ± 84 0.59
D-dimers (μg/L) 2617 ± 6353 4456 ± 4957 0.0032
ISTH score 1.6 ± 1.3 2.6 ± 0.9 0.041
White blood cell count (103/μL) 10.0 ± 4.4 11.1 ± 5.2 0.42
Flow cytometry
TNF-α (pg/mL) 0.17 ± 0.8 0.65 ± 1.5 0.091
IL-10 (pg/mL) 19.4 ± 90 9.4 ± 16.2 0.50
sCD40L (pg/mL) 88.8 ± 81.8 53.3 ± 43.6 0.89
IL-17A (pg/mL) 9.1 ± 12.2 7.6 ± 15.5 0.31
IL-6 (pg/mL) 459 ± 2673 162 ± 164 0.94
IL-7 (pg/mL) 2.9 ± 3.7 1.4 ± 1.7 0.65
IFN-γ (pg/mL) 0.14 ± 0.91 0 0.99
Platelet-Fg (%) 28.1 ± 27.8 56.5 ± 31.2 0.0054
Platelet-Fg (MFI) 1770 ± 1266 2752 ± 1359 0.0026
Platelet-PS (%) 2.9 ± 2.4 3.5 ± 2.7 0.61
Platelet-PS (MFI) 29.8 ± 15.1 37 ± 18.3 0.068
Platelets-neutrophils (%) 3.4 ± 5 4.4 ± 6.2 0.72
Platelets-neutrophils (CD61 MFI) 313 ± 127 323 ± 137 0.72
Platelets-monocytes (%) 19.8 ± 23.1 22.1 ± 25.5 0.73
Platelets-monocytes (CD61 MFI) 1413 ± 2462 1569 ± 3182 0.82
Null values for TNF-α and IFN-γ correspond to values under the level of detection (3.8 pg/ml)
Platelet-Fg platelet-bound fibrinogen, platelet-PS, platelets expressing P-selectin on their surface, MFI median fluorescence
intensity, % percentage of positive cells for the indicated marker
aResults are expressed as means ± SD
bLogistic regression
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increased significantly from T2 to the time of sepsis diagnosis (Additional file 1:
Figure S2).
Platelet markers at admission and sepsis prediction
All potential predictors of sepsis (P < 0.10) recorded at ICU admission (T1) were com-
bined into a stepwise logistic regression analysis. As diagnosis of sepsis includes organ
dysfunction, SOFA score was not included in our regression model. It turned out that
platelet-Fg % levels at T1 (P = 0.0031) and admission for acute brain injury (P = 0.012)
were the only independent predictors of sepsis occurrence. By ROC curve ana-
lysis (Fig. 2), an optimal cutoff point equal to 50% was derived for platelet-Fg %
(AUC = 0.75) to discern patients who will later develop sepsis from those who
will not. The number of patients who developed sepsis was respectively equal to
13 (46.4%) for the 28 patients with platelet-Fg >50% and to 6 (8.6%) for the 70
patients with platelet-Fg <50% (data missing for one patient). As shown in
Table 3, when accounted for SOFA score at admission (cutoff value of 8), in pa-
tients with elevated SOFA and platelet-Fg >50%, the risk of sepsis rose up to
85.7%. By contrast, in patients with low SOFA and platelet-Fg <50%, the occur-
rence of sepsis was almost negligible (3.8%).
Discussion
The major findings of this study concern the clear relationship between patient
levels of fibrinogen binding to circulating platelets (platelet-Fg) measured upon
ICU admission and sepsis occurrence, regardless of the patient’s baseline clinical
characteristics. In particular, the study demonstrated that for patients presenting
a SOFA score ≥8, platelet-Fg % level above 50 predicted sepsis with a high accur-
acy. Importantly, neither platelet membrane-bound P-selectin expression plasma
levels of sCD40L nor any other standard hemostasis parameter showed similar
Fig. 1 Serial measurements of levels of platelet-bound fibrinogen (platelet-Fg) for patients who developed
sepsis. Platelet-Fg levels were analyzed by flow cytometry on the day of ICU admission (T1), after 48 h (T2),
at the time of sepsis diagnosis (Tx), and 7 days later (Tx + 7). Median values of percentages of Fg-positive
platelets and IQR are shown (P value: Kruskal-Wallis test)
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predictive value as platelet-Fg. The optimal timing of measurement was also de-
termined since only levels obtained within 24 h after ICU admission and not
48 h later were associated with sepsis occurrence, thus saving blood sampling in
future studies. Platelet-Fg levels can be obtained in 1 h by using whole blood
flow cytometry in unstimulated samples. Thus, this work provides the clinician
with a simple and practical tool to assess the risk of sepsis in critically ill pa-
tients admitted to the ICU.
To date, several clinical studies investigated platelet markers in various conditions
of critical illness. However, none of them searched for a potential association of these
platelet markers with a risk for sepsis. Most of these studies described altered platelet
phenotype in injured patients, characterized by either differential expression of
platelet activation markers or platelet dysfunction as compared to healthy controls
[23–28]. In ischemic stroke, two studies showed increased expression of platelet P-
selectin and fibrinogen binding to platelets as compared to controls [25, 29]. The
latter finding is interesting in view of our results, in particular since predisposition to
severe pneumonia is clinically well established in such patients [30, 31]. Unfortu-
nately, no association was searched between high levels of the biomarker and pneu-
monia. Several other clinical studies focusing on platelets as potential biomarkers for
Table 3 Risk stratification of patients according to sepsis development during ICU stay
SOFA <8 SOFA ≥8
Platelet-Fg (%) Platelet-Fg (%)
Development of sepsis <50 ≥50 <50 ≥50
Yes (N = 19) 2 1 4 12
No (N = 79) 51 13 13 2
Total 53 14 17 14
Risk of sepsis (%) 3.8 7.1 23.5 85.7
SOFA score and Platelet-Fg (%) plasma levels recorded on admission
Fig. 2 Predictive value of platelet-Fg (%) obtained at admission. ROC curve analysis of sepsis prediction
based on platelet-Fg is shown
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sepsis diagnosis and prognostication have been carried out but almost all concerned
patients with sepsis as an inclusion criterion [32, 33].
Despite multiple experimental data demonstrating antimicrobial activity of plate-
lets and a role for platelet aggregation in limiting pathogen growth and dissemin-
ation in the vasculature [3, 6], direct clinical evidence from human studies was
lacking and there are no epidemiologic data showing that platelet function inhib-
ition affects sepsis prediction or prognosis. The present observational prospective
study provides the first clinical evidence that, in patients with critical illness and
related organ dysfunction, platelets may intervene in the dysregulated host
response to infection leading to sepsis. Although demonstration of a causal link re-
quires further investigation, we speculate that injury-associated platelet activation
and subsequent fibrinogen binding may alter platelet ability to recognize bacterial
components, some of which are ligands of αIIbβ3 [34, 35], and affect their ability
to alert and recruit cells of the immune system [8]. Our observation that platelet-
Fg weakly correlates with D-dimer levels suggests that fibrinogen binding to plate-
lets and the activation of coagulation could be driven by the same factors. In
injured patients, plasma fibrinogen would both bind platelets and be actively con-
verted into fibrin; fibrinolysis would then increase D-dimer levels.
Antiplatelet drugs have beneficial and detrimental effects in systemic inflamma-
tion and in organ dysfunction, as shown in preclinical models and in humans
[36–38]. Their usage has been variably associated with sepsis prognosis [39, 40].
In this study, we found no protective effect of aspirin against sepsis [41]. Our re-
sults are in line with a recent propensity-based analysis of 972 patients admitted
for sepsis in which no association between aspirin therapy and sepsis prognosis
could be evidenced [42]. Our results however differ in that they encompassed the
period before sepsis, a period during which the abovementioned authors could
not assess the potential benefits of aspirin. In addition, we could not find any
association between aspirin therapy and the levels of platelet activation, which
suggests that platelet activation pathways independent of thromboxane A2 pro-
duction could be involved in the patient’s platelet response to injury.
Limitations
The study has a number of limitations. The small sample size and the predomin-
ance of elective surgical patients call for caution when interpreting results. Also,
possible confounders such as immunomodulatory properties of anesthetic drugs
were not taken into account at this stage. The findings of this pilot study call for
a confirmatory prospective evaluation focusing on fibrinogen levels on platelets in
a larger cohort. In our study, the platelet activation markers analyzed, namely
levels of fibrinogen, platelet P-selectin expression, platelets-leukocytes aggregates,
and sCD40L, behaved differently in their ability to predict sepsis development,
which might reflect differences in platelet activation mechanisms or sequences. It
has indeed been proposed that platelet activation, in terms of P-selectin expres-
sion and fibrinogen binding, and release of immunological molecules (sCD40L,
RANTES) result from independent signaling pathways [43]. The utility of other
markers, such as platelet microparticles or soluble glycoprotein VI, should be
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analyzed, since the latter is shed from platelet surface and increases in patients
with DIC [44].
Conclusions
In critically ill patients with comorbidities and post-trauma or post-surgical injury,
platelet abnormalities are associated with altered host defense mechanisms. We actually
found that admission levels of fibrinogen binding to platelets of ICU patients were pre-
dictive of later sepsis acquisition. Combining it with stratification based on SOFA score
at admission has a higher predictive ability. Hence, our observations could trigger non-
specific preventive interventions such as better supportive care or prophylactic antibi-
otics as well as research aiming at developing a specific therapeutic tool. Also, the fact
that the identified marker was independent of aspirin use might have important future
therapeutic implications regarding its actual worldwide implementation of primary or
secondary prophylaxis.
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